News: AstraZeneca

03.09.2010 | BioSpace: AstraZeneca PLC (AZN)'s Seroquel XR Gets EC Approval

LONDON (Reuters) - Drugmaker AstraZeneca (AZN.L) said on Thursday the European Commission had approved Seroquel XR as an add-on treatment for major depressive disorder for patients that had not responded well to an existing antidepressant

[Read article]

[Source: BioSpace]

01.09.2010 | ScienceDaily: Lower Blood Pressure May Preserve Kidney Function in Some Patients

ScienceDaily (Sep. 1, 2010) Intensively treating hypertension in some African Americans with kidney disease by pushing blood pressure well below the current recommended goal may significantly decrease the number who lose kidney function and require dialysis, suggests a Johns (…)

[Read article]

[Source: ScienceDaily]

02.09.2010 | Medical News Today: Lower Blood Pressure May Preserve Kidney Function In Some Patients

Intensively treating hypertension in some African Americans with kidney disease by pushing blood pressure well below the current recommended goal may significantly decrease the number who lose kidney function and require dialysis, suggests a Johns Hopkins-led study publishing (…)

[Read article]

[Source: Medical News Today]

02.09.2010 | Business Wire: Research and Markets: Examine Norway's Pharmaceutical Market with This Essential Analysis to 2014 As the Market Generated Total Revenues of $2,011.5 Million In 2009 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/ebf598/norway_pharmaceuti) has announced the addition of the "Norway Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed fluctuating growth rates in the (…)

[Read article]

[Source: Business Wire]

02.09.2010 | BioSpace: Seattle Genetics, Inc. (SGEN) Achieves Milestone under Antibody-Drug Conjugate Collaboration with Agensys, Inc., an Affiliate of Astellas Pharma Inc. (YPH.BE); Seattle Has Received $130 Million to date With Potential to Receive $2.7 Billion

BOTHELL, Wash.-(BUSINESS WIRE)-Seattle Genetics, Inc. (Nasdaq: SGEN - News) announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. The milestone was triggered (…)

[Read article]

[Source: BioSpace]

02.09.2010 | BioSpace: Gene Logic Inc. (GLGC) Announces Appointment of Norrie Russell as President

Gaithersburg, Maryland, USA and Hyderabad, Andhra Pradesh, India, September 2, 2010: Gene Logic, an Ocimum Biosolutions company, a leading provider of genomic solutions, is pleased to announce the appointment of Norrie J. W. Russell, Ph. D., as the President of the company. (…)

[Read article]

[Source: BioSpace]

31.08.2010 | Business Wire: Research and Markets: Philippines Pharmaceuticals and Healthcare Report Q4 2010 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/66a1b1/philippines_pharma) has announced the addition of the "Philippines Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Philippines Pharmaceuticals and (…)

[Read article]

[Source: Business Wire]

31.08.2010 | BioSpace: Flagship Biosciences LLC Creates Scientific Advisory Board

Flagstaff, AZ (PRWEB) August 27, 2010 - Flagship Biosciences LLC, a provider of digital pathology services, has formed a Scientific Advisory Board composed of experienced leaders in the pharmaceutical industry. Flagship is a pathologist-owned company committed to improving the (…)

[Read article]

[Source: BioSpace]

30.08.2010 | Business Wire: Research and Markets: This Essential Analysis Examines the Historical and Forecast Performance for Eli Lilly In the Prescription Pharma Sector | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/37adf0/eli_lilly_co_p) has announced the addition of the "Eli Lilly & Co.: PharmaVitae Profile" company profile to their offering. Introduction This analysis examines the historical and (…)

[Read article]

[Source: Business Wire]

30.08.2010 | Business Wire: Research and Markets: This Report Highlights Sweden's Pharmaceutical Sector in Terms of Market Share, Key Trends, Market Players and Competitive Scenario in the Market | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/b87073/sweden_pharmaceuti) has announced the addition of the "Sweden Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed fluctuating growth rates in the (…)

[Read article]

[Source: Business Wire]

30.08.2010 | Business Wire: Research and Markets: This Analysis Examines the Historical and Forecast Performance for Johnson & Johnson in the Ethical Pharmaceutical Sector | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/aabcf1/johnson_johnson) has announced the addition of the "Johnson & Johnson: PharmaVitae Profile" company profile to their offering. Introduction This analysis examines the historical and (…)

[Read article]

[Source: Business Wire]

30.08.2010 | BioSpace: AstraZeneca PLC (AZN) s Brilinta Outshines Rival Sanofi-Aventis (France) (SASY.PA)'s Plavix in Studies

STOCKHOLM (Reuters) - Gene testing is shaping up to be a marketing battleground for new blood thinners like AstraZeneca's Brilinta, underscoring the power and limitations of genetics as a tool to predict medical outcomes.

[Read article]

[Source: BioSpace]

30.08.2010 | BioSpace: U.S. FDA Wants More Information On AstraZeneca PLC (AZN) Lung Drug

LONDON, Aug 30 (Reuters) - AstraZeneca's MedImmune biologics unit has been asked by U.S regulators for more information on its infant lung drug motavizumab after drug regulatory advisors recommended against approving it in June.

[Read article]

[Source: BioSpace]

29.08.2010 | Medical News Today: Experimental Anti-clotting Drug Brilinta Needs No Genetic Testing, Unlike Plavix

Experimental anti-clotting medication Brilinta (ticagrelor) works on patients, regardless of whether they had the genetic variability that has been previously shown to affect a patients' responses to Plavix (clopidogrel), Sanofi-Aventis' blockbuster medication, AztraZeneca PLC (…)

[Read article]

[Source: Medical News Today]

27.08.2010 | Medical News Today: Lotus Pharmaceuticals Enter R-Bambuterol(R) Clinical Trial I

Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC"), announced that it has entered R-Bambuterol(R) Clinical Trial I on-schedule and is (…)

[Read article]

[Source: Medical News Today]

27.08.2010 | Medical News Today: American Lung Association Joins Lung Cancer Clinical Trial Call To Action Campaign

The American Lung Association is encouraging patients with lung cancer to take charge of their diagnosis and learn about clinical trials through the Lung Cancer Clinical Trial Call to Action campaign. This service provides personalized education to quickly identify trial (…)

[Read article]

[Source: Medical News Today]

26.08.2010 | Business Wire: Research and Markets: This Essential World Pharmaceutical Market Analysis Digest Guide with Forecasts Predicts the Market Will Stabilize the Years Up To 2014 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e03d6e/world_pharmaceutic) has announced the addition of the "World Pharmaceutical Market Analysis - A Digest Guide, 2010-2014" report to their offering. World Pharmaceutical Market (…)

[Read article]

[Source: Business Wire]

26.08.2010 | Business Wire: Research and Markets: Examine the Europe Pharmaceutical Market with This Essential Analysis as the Market is Expected to Decelerate Followed by a Slow and Graduate Increase over the Years up to 2014 to Fluctuate over the Years up to 2014 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/1683a8/europe_pharmaceuti) has announced the addition of the "Europe Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed quite healthy growth rates in the (…)

[Read article]

[Source: Business Wire]

26.08.2010 | Business Wire: Maven Semantic: Antibacterial Research Database | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Antibacterial research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise visible (…)

[Read article]

[Source: Business Wire]

26.08.2010 | Business Wire: Research and Markets: Russian Pharmaceutical Market Analysis, 2010-2014 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/a539e9/russia_pharmaceuti) has announced the addition of the "Russia Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed fluctuating growth rates in the (…)

[Read article]

[Source: Business Wire]

26.08.2010 | Business Wire: Research and Markets: Examine the United Kingdom Pharmaceutical Market with This Essential Analysis and Forecast to 2014 As the Market Generated Total Revenues of $25,681.9 Million In 2009 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/57b994/united_kingdom_pha) has announced the addition of the "United Kingdom Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed fluctuating growth rates (…)

[Read article]

[Source: Business Wire]

26.08.2010 | Business Wire: Research and Markets: Italian Pharmaceutical Market Analysis, 2010-2014 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/5e92bb/italy_pharmaceutic) has announced the addition of the "Italy Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed fluctuating growth rates in the (…)

[Read article]

[Source: Business Wire]

26.08.2010 | Business Wire: Research and Markets: Spain Pharmaceutical Market Report - 2010-2014 Analysis | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/bc6aea/spain_pharmaceutic) has announced the addition of the "Spain Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed fluctuating growth rates in the (…)

[Read article]

[Source: Business Wire]

25.08.2010 | Medical News Today: People At 'Intermediate Risk' Of Heart Disease With Elevated HsCRP Benefit From Statin Therapy Even If Cholesterol Levels Are Normal

Women and men with a 10-year cardiovascular disease risk of 5 percent or more and normal cholesterol levels but high levels of hsCRP, a protein associated with inflammation, could reduce their risk substantially with statin therapy, according to new research. The study, (…)

[Read article]

[Source: Medical News Today]

25.08.2010 | Medical News Today: FDA's New Safety Controls For LABA-Containing Drugs Will Impact Prescribing Of Single-Agent ICS And LABA/ICS Combination Therapies

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that some surveyed physicians indicate that they will decrease their overall prescribing of long-acting beta2 agonists (LABA)/inhaled corticosteroids (ICS) (…)

[Read article]

[Source: Medical News Today]

25.08.2010 | Business Wire: Research and Markets: Educating the Market: Creating Value Through Support of Continuing Medical Education 2010 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e9e8b4/educating_the_mark) has announced the addition of the "Educating the Market: Creating Value Through Support of Continuing Medical Education 2010" report to their offering. Educating (…)

[Read article]

[Source: Business Wire]

25.08.2010 | Business Wire: Research and Markets: Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/2ba1fa/commercial_insight) has announced the addition of the "Commercial Insight: Antihormonal Cancer Therapies - Leading brands strive to minimize generic sales erosion" report to their (…)

[Read article]

[Source: Business Wire]

23.08.2010 | Business Wire: Research and Markets: Australia Pharmaceutical Market Overview - Reforms and Continued Price Cuts Will Change the $80 Billion Healthcare Landscape | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/504cfd/australia_pharmace) has announced the addition of the "Australia Pharmaceutical Market Overview - Reforms and continued price cuts will change the healthcare landscape" report to (…)

[Read article]

[Source: Business Wire]

24.08.2010 | Business Wire: Research and Markets: Netherlands Pharmaceutical Market Analysis 2010-2014 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/a7beab/netherlands_pharma) has announced the addition of the "Netherlands Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed fluctuating growth rates in (…)

[Read article]

[Source: Business Wire]

24.08.2010 | Business Wire: Pharmaceutical Industry Executive Dr. Sidney Mazel Joins PRTM as Executive Vice President | Business Wire

WASHINGTON-(BUSINESS WIRE)-Dr. Sidney Mazel joins global management consulting firm PRTM as executive vice president of transaction services for the health care business group. In this role, he will manage PRTM s acquisition, divestiture and integration services for the firm (…)

[Read article]

[Source: Business Wire]

24.08.2010 | Business Wire: Research and Markets: Canadian Pharmaceutical Market Analysis 2010 to 2014 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/89c28c/canada_pharmaceuti) has announced the addition of the "Canada Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed quite healthy growth rates in the (…)

[Read article]

[Source: Business Wire]

24.08.2010 | Business Wire: Research and Markets: France Pharmaceutical Market Analysis, 2010-2014 - Revenue, Geographic Regions, Product Types, and Market Players | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/c339b0/france_pharmaceuti) has announced the addition of the "France Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed fluctuating growth rates in the (…)

[Read article]

[Source: Business Wire]

01.10.2010 | NCBI PubMed: Introduction to the special issue on Alzheimer's disease.

Neuropharmacology. |-| Pangalos MN, Randall AD. |-| EVP, Innovative Medicines AstraZeneca, Room 11F63, Mereside, Alderley Park, SK10 4TG, UK.

[Read article]

[Source: NCBI PubMed]

30.07.2010 | NCBI PubMed: Discovery of 8-azabicyclo3.2.1octan-3-yloxy-benzamides as selective antagonists of the kappa opioid receptor. Part 1.

Initial high throughput screening efforts identified highly potent and selective kappa opioid receptor antagonist 3 (kappa IC(50)=77nM; mu:kappa and delta:kappa IC(50) ratios 400) which lacked CNS exposure in vivo. Modification of this scaffold resulted in development of a (…)

[Read article]

[Source: NCBI PubMed]

18.08.2010 | NCBI PubMed: A commentary on the process of peer review and pathology data locking.

Exp Toxicol Pathol. |-| McKay JS, Barale-Thomas E, Bolon B, George C, Hardisty J, Manabe S, Schorsch F, Teranishi M, Weber K. |-| AstraZeneca, UK.

[Read article]

[Source: NCBI PubMed]

23.08.2010 | Business Wire: Research and Markets: Cardiovascular Sales Proved the Most Lucrative For the Hungary Pharmaceuticals Market in 2009, Generating Total Revenues of $581.8 Million | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/4e1e2d/hungary_pharmaceut) has announced the addition of the "Hungary Pharmaceutical Market Analysis, 2010-2014" report to their offering. Having displayed fluctuating growth rates in the (…)

[Read article]

[Source: Business Wire]

20.08.2010 | NCBI PubMed: Observed peptide pI and retention time shifts as a result of post-translational modifications in multidimensional separations using narrow-range IPG-IEF.

Modified peptides constitute a sub-population among the tryptic peptides analyzed in LC-MS based shotgun proteomics experiments. For larger proteomes including the human proteome, the tryptic peptide pool is very large, which necessitates some form of sample fractionation. By (…)

[Read article]

[Source: NCBI PubMed]

03.08.2010 | NCBI PubMed: SAR development of a series of 8-azabicyclo3.2.1octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2.

Further structure activity relationship studies on a previously reported 8-azabicyclo[3.2.1]octan-3-yloxy-benzamide series of potent and selective kappa opioid receptor antagonists is discussed. Modification of the pendant N-substitution to include a cyclohexylurea moiety (…)

[Read article]

[Source: NCBI PubMed]

18.08.2010 | NCBI PubMed: Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective.

Innovation is essential for the identification of novel pharmacological therapies to meet the treatment needs of patients with psychiatric disorders. However, over the last 20 yr, in spite of major investments targets falling outside the classical aminergic mechanisms have (…)

[Read article]

[Source: NCBI PubMed]

19.08.2010 | BioSpace: Skyepharma PLC (SKYEF) Interim Report

LONDON, ENGLAND, 19 August 2010 Summary of unaudited results for the six months ended 30 June 2010 H1 2010 H1 2009 £m £m Results Revenue 29.3 25.5 Research and development expenses (10.0) (10.3) Operating profit 8.6 5.4 Net profit/(loss) after tax (post exceptional) 0.9 (6.1) (…)

[Read article]

[Source: BioSpace]

18.08.2010 | Business Wire: Research and Markets: Biomarkers: Discovery Techniques and Applications - a Global Market Overview | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/bd425b/biomarkers_discov) has announced the addition of the "Biomarkers: Discovery Techniques and Applications A Global Market Overview" report to their offering. Biomarkers: Discovery (…)

[Read article]

[Source: Business Wire]

18.08.2010 | BioSpace: Limerick BioPharma Inc. Names Jill Carroll to Serve as Vice President of Strategic Corporate Development

SOUTH SAN FRANCISCO, Calif. August 17, 2010 Limerick BioPharma, Inc., a developer of innovative therapies that help cells pump unwanted or toxic substances away from vulnerable tissues, has announced that Jill Carroll has joined the firm as Vice President of Strategic Corporate (…)

[Read article]

[Source: BioSpace]